

In the Claims

1. (Currently Amended) An inclusion complex of ~~butylphthalide with cyclodextrin or cyclodextrin derivatives~~, comprising butylphthalide and a cyclodextrin selected from the group consisting of α -cyclodextrin, β -cyclodextrin and γ -cyclodextrin or cyclodextrin derivative derivatives[[,]] selected from the group consisting of hydroxyethyl- β -cyclodextrin, hydroxypropyl- β -cyclodextrin, dihydroxypropyl- β -cyclodextrin, methyl- β -cyclodextrin, glucose cyclodextrin, maltose cyclodextrin, meltotriose cyclodextrin, carboxymethyl cyclodextrin and sulfonylalkyl cyclodextrin, wherein the molar ratio of butylphthalide to the cyclodextrin or the cyclodextrin derivatives is 1:1-10.

2. (Previously Presented) The inclusion complex according to claim 1, wherein said butylphthalide is D, L-mixed or levorotatory butylphthalide.

3-4. (Cancelled)

5. (Currently Amended) The inclusion complex according to claim 1 or [[4]] 2, wherein the cyclodextrin derivative is hydroxypropyl- β -cyclodextrin.

6. (Original) A process for preparing the inclusion complex of butylphthalide with cyclodextrin or cyclodextrin derivatives, comprising the steps of adding cyclodextrin or cyclodextrin derivatives into a suitable solvent vehicle to obtain a solution with a concentration of 5-60%, adding butylphthalide into the solution, stirring to obtain a liquid inclusion complex of butylphthalide with cyclodextrin or cyclodextrin derivatives.

7. (Previously Presented) The process according to claim 6, further comprising the step of drying the liquid inclusion complex of butylphthalide with cyclodextrin or cyclodextrin

derivatives to obtain a solid inclusion complex of butylphthalide with cyclodextrin or cyclodextrin derivatives.

8. (Previously Presented) The process according to claim 6, further comprising the steps of concentrating the liquid inclusion complex of butylphthalide with cyclodextrin or cyclodextrin derivatives into a solution with a concentration of 10-15% (W/V), cooling to obtain white precipitate, filtering, and drying to obtain a solid inclusion complex of butylphthalide with cyclodextrin or cyclodextrin derivatives.

9. (Original) A process for preparing the inclusion complex of butylphthalide with cyclodextrin or cyclodextrin derivatives, comprising the steps of placing the cyclodextrin or cyclodextrin derivatives into a colloid mill or mortar, adding a suitable solvent vehicle to obtain a paste, adding butylphthalide into the paste, filtering, and drying to obtain a solid inclusion complex of butylphthalide with cyclodextrin or cyclodextrin derivatives.

10. (Currently Amended) A process for preparing the inclusion complex of butylphthalide with cyclodextrin or cyclodextrin derivatives, comprising the steps of adding cyclodextrin or cyclodextrin derivatives into a suitable solvent vehicle to obtain a solution with a concentration of 5-60%, dissolving butylphthalide into a selected amount of ethanol with a purity of 99%, mixing the two solutions, stirring, and drying to obtain a solid inclusion complex of butylphthalide with cyclodextrin or cyclodextrin derivatives.

11. (Previously Presented) The process according to claim 6, 9, or 10, wherein said suitable solvent vehicle is selected from the group consisting of water, ethanol, methanol, propanol, isopropanol, ethylene glycol, propylene glycol, glycering, acetone, and a mixed solvent vehicle of any two or more of the solvent vehicles.

12. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of the inclusion complex according to claim 1 and a suitable carrier.

13. (Previously Presented) The pharmaceutical composition according to claim 12 in a liquid dosage form.

14. (Previously Presented) The pharmaceutical composition according to claim 12 in a solid dosage form.

15. (Previously Presented) A method of treating ischemia-induced disease comprising administering a therapeutically effective amount of the inclusion complex according to claim 1 to a patient.

16. (Previously Presented) A method of treating thrombosis comprising administering a therapeutically effective amount of the inclusion complex according to claim 1 to a patient.

17. (New) The pharmaceutical composition according to claim 11, wherein the liquid dosage form is selected from the group consisting of infusion, injection, injectable powder, liquids for oral administration and syrup.

18. (New) The pharmaceutical composition according to claim 13, wherein the solid dosage form is selected from the group consisting of tablets, capsules, granules and dispersible tablets.